Last reviewed · How we verify
PAD combination
PAD combination is a multi-drug regimen that combines proteasome inhibition, immunomodulation, and corticosteroid activity to induce apoptosis and suppress proliferation in hematologic malignancies.
PAD combination is a multi-drug regimen that combines proteasome inhibition, immunomodulation, and corticosteroid activity to induce apoptosis and suppress proliferation in hematologic malignancies. Used for Multiple myeloma, relapsed/refractory, Multiple myeloma, newly diagnosed.
At a glance
| Generic name | PAD combination |
|---|---|
| Also known as | -vincristine, -doxorubicin, -dexamethasone, Induction Therapy |
| Sponsor | Cooperative Study Group A for Hematology |
| Drug class | Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid) |
| Target | 26S proteasome; cereblon (CRBN); glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
PAD typically refers to a combination of Proteasome inhibitor (Bortezomib or similar), an IMiD (Immunomodulatory drug such as Pomalidomide or Lenalidomide), and Dexamethasone. Bortezomib inhibits the 26S proteasome, leading to accumulation of pro-apoptotic proteins. The IMiD enhances immune activation and has direct anti-proliferative effects. Dexamethasone provides additional anti-inflammatory and anti-proliferative activity.
Approved indications
- Multiple myeloma, relapsed/refractory
- Multiple myeloma, newly diagnosed
Common side effects
- Peripheral neuropathy
- Thrombocytopenia
- Anemia
- Infection
- Fatigue
- Nausea
Key clinical trials
- Effects of Post-Isometric Relaxation and Myofascial Release on Low Back Pain With Lower Cross Syndrome (NA)
- Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder (NA)
- Anatomical Evaluation of Supraspinatus Through Ultrasonography and Biomechanical Measurements Following Different Combinations of Physical Therapies in Patients of Supraspinatus Tendinitis (NA)
- Vessel Recoil in Specific CLTI Populations
- ELISA in Relapsed/Refractory MM (PHASE2)
- Spinal Cord Stimulation for Parkinson's Disease Rehabilitation (NA)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PAD combination CI brief — competitive landscape report
- PAD combination updates RSS · CI watch RSS
- Cooperative Study Group A for Hematology portfolio CI